Apoptosis Inhibitor of Macrophage (AIM) Explained

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

Apoptosis inhibitor of macrophage (AIM) is a secreted glycoprotein of the scavenger receptor cysteine-rich (SRCR) superfamily that is produced mainly by macrophages and circulates in blood bound to immunoglobulin M (IgM) pentamers. It suppresses macrophage apoptosis and promotes the clearance of dead cells, debris, and lipids, which places it at the center of tissue repair, lipid handling, and inflammatory balance.

AIM matters because it sits at a junction that most signaling proteins avoid. It is simultaneously a survival factor for the very cell that secretes it, an opsonin that tags cellular garbage for removal, and a lipid-regulating protein that can push macrophages toward a foamy, lipid-laden state. Depending on the tissue and the disease context, those same properties can protect an organ or damage it. The AIM knockout mouse makes this tension visible: removing one secreted protein changes outcomes in atherosclerosis, obesity, kidney injury, myocardial infarction, and several infection models [1][2][3].

The gene and protein carry several names that appear interchangeably in the literature. AIM is encoded by CD5L (CD5 molecule-like), and the protein is also called CD5L, Api6, and Spalpha. Human CD5L and mouse Aim are orthologs, but they are not identical, and species differences in IgM binding affinity are large enough to change how the protein behaves in circulation [4].

What AIM Is and Where It Comes From

AIM belongs to the SRCR superfamily, a group of proteins defined by one or more scavenger receptor cysteine-rich domains. These domains are ancient, disulfide-stabilized folds that bind a wide range of ligands, including lipids, glycans, and modified self-proteins. That binding promiscuity is exactly why AIM can act as an opsonin: it coats targets that need to be removed.

The primary source of AIM is the macrophage. Tissue macrophages secrete it, and alveolar macrophages in the lung are a well-documented source [5]. It is not exclusive to macrophages. Epicardial adipose tissue releases CD5L, and the trabecular meshwork cells of the eye respond to it, which shows that the protein reaches compartments well beyond the mononuclear phagocyte system [6][7].

In blood, most AIM is not free. It travels bound to IgM pentamers, and this association is the single most important fact for understanding its biology. IgM binding stabilizes AIM and keeps circulating levels high while limiting its activity. The protein becomes functionally available only when it dissociates from IgM, and that dissociation is the regulated step. In acute kidney injury, for example, high salt loading worsened injury largely by reducing AIM dissociation from the IgM pentamer, and free AIM was the fraction required to clear intratubular debris [8].

The Domain Architecture

AIM is built from SRCR domains. The canonical mammalian protein carries three SRCR domains, and the N-terminal region mediates the association with IgM. The number of domains is not fixed across species. In cats, AIM exists as both a three-domain (37 kDa) and a four-domain (45 kDa) variant generated by duplication of exon 3, and feline AIM binds IgM roughly 1000-fold more tightly than murine AIM because of a species-specific positively charged cluster in its third SRCR domain [4]. That single observation is a useful reminder that "AIM" is a family of orthologous proteins with real biochemical differences, not one invariant molecule.

How AIM Works: Mechanism Step by Step

Understanding AIM requires following it through four sequential steps.

Step 1: Secretion by macrophages. Macrophages synthesize AIM and release it into the local environment and into circulation. Expression is not constant. It rises with inflammatory stimuli and with lipid loading, and it is induced downstream of interleukin-10 (IL-10) signaling through STAT3, which binds the AIM promoter directly [9].

Step 2: IgM binding in blood. Once secreted, AIM associates with IgM pentamers. This keeps the protein stable but largely inactive. The AIM/IgM ratio in blood therefore reflects the balance between stored and available protein, and it changes with disease state [5].

Step 3: Dissociation and local action. At sites of injury or inflammation, AIM dissociates from IgM and becomes free AIM. Free AIM is the active fraction. It binds its receptor and engages downstream clearance and survival pathways [8].

Step 4: Receptor engagement. CD36 is the main receptor for AIM, and the two proteins colocalize in target cells such as trabecular meshwork cells [7]. Kidney injury molecule-1 (KIM-1) is a second, context-specific partner. In the kidney, AIM-dependent repair of lethal acute kidney injury requires KIM-1, because recombinant AIM was not effective in KIM-1-deficient mice [8]. This is a clean genetic demonstration that AIM does not act alone, it acts as a cofactor for a phagocytic receptor.

Why It Blocks Apoptosis

The name describes the founding observation: AIM inhibits apoptosis in macrophages. Mechanistically, AIM supports macrophage survival and shifts the cell toward an alternatively activated, M2-like state. It also suppresses inflammasome activation. IL-10-induced reduction of IL-1β production and caspase-1 activation was reversed in macrophages from AIM-deficient mice, and recombinant AIM inhibited ASC speck formation, the assembly step that drives inflammasome signaling [9]. By damping this pathway, AIM limits a major source of inflammatory cytokine release.

Why It Clears Debris

AIM functions as an opsonin. It coats apoptotic and necrotic cells and augments their recognition by phagocytic receptors. In the kidney, this means proximal tubular epithelial cells can clear the dead cells and casts that obstruct tubules after ischemia-reperfusion injury. Recombinant AIM enhanced clearance of necrotic cells by both murine and human tubular epithelial cells in vitro, and in transplanted mice it reduced renal dysfunction, tubular cell death, tissue damage, tubular obstruction, and local and systemic inflammation [10]. The same logic applies in the eye, where AIM stimulated phagocytosis in trabecular meshwork cells and AIM-deficient mice were slower to clear accumulated pigment and debris after laser-induced pressure elevation [7].

Why It Moves Lipids

AIM regulates lipid metabolism in macrophages and other cells. It promotes lipid droplet accumulation, and this is the mechanism behind foamy macrophage formation. In Mycobacterium avium infection, AIM drives the foamy macrophage phenotype that the bacteria exploit as a replicative niche. AIM knockout mice formed fewer foamy macrophages, had reduced lipid droplet accumulation, and carried a lower bacterial load in the lungs [3]. A companion study showed that recombinant AIM increased bacterial numbers in the lung, while anti-AIM antibodies reduced them and increased the percentage of apoptotic infected cells [11]. In myocardial infarction, AIM provokes efflux of saturated free fatty acids through lipolysis, which activates TLR-4 and drives inflammation [1].

AIM Functions Across Tissues

The table below summarizes the main tissue-specific actions of AIM and the model systems that revealed them.

The AIM Knockout Mouse: What Losing One Protein Reveals

The Aim knockout mouse is the workhorse of this field because AIM is secreted, so removing the gene removes both the local and the circulating pools. The phenotypes cluster around three themes: survival, inflammation, and lipid handling.

Macrophage survival and inflammation. AIM was named for its ability to keep macrophages alive. When AIM is absent, inflammatory macrophage populations behave differently. In aortic aneurysm models, anti-AIM antibody treatment reduced the number of inflammatory M1 macrophages and increased caspase-3 expression in the aortic wall, which indicates that blocking AIM pushes those cells toward apoptosis [13]. That is the inverse of the founding observation and confirms the survival function in vivo.

Atherosclerosis and cardiovascular injury. AIM exacerbates chronic inflammation and contributes to arteriosclerosis [2]. In myocardial infarction, AIM knockout mice had smaller infarcts, reduced heart weight-to-body weight ratio, less myocardial fibrosis, and improved 28-day survival compared with wild-type mice, alongside reduced plasma free fatty acids and decreased myocardial IRAK4 and NF-κB activity [1]. In aortic aneurysm, anti-AIM antibody reduced aortic diameter at four weeks (2.1 mm versus 2.7 mm) and reduced IL-6, TNF-α, and MCP-1 expression [13].

Obesity and lipid phenotypes. AIM regulates lipid metabolism, and the knockout changes systemic lipid handling. In a community-based cohort, higher baseline serum AIM was associated with an increased risk of developing metabolic dyslipidemia in women, with a hazard ratio of 1.84 for the highest versus lowest tertile, and the association held after multivariable adjustment [14]. Cross-sectionally, higher AIM tracked with elevated acylcarnitines and tricarboxylic acid cycle intermediates, which points to altered mitochondrial fuel handling.

Kidney repair. AIM is required for efficient recovery from acute kidney injury. Recombinant AIM rescued mice from lethal ischemia-reperfusion injury, and the effect depended on KIM-1 [8]. In kidney transplantation models, recombinant AIM reduced delayed graft function markers [10]. Dogs with acute kidney injury showed AIM predominantly in urine rather than serum, which suggests renal handling of the protein changes with injury [15].

Infection outcomes. The infection data are the most context-dependent. In M. avium infection, AIM worsens the outcome by promoting foamy macrophages and IL-10-driven suppression of M1 responses, and AIM knockout mice cleared bacteria better [3]. In sepsis, AIM blockade improved survival, reduced inflammation and tissue injury, and limited bacterial dissemination, while recombinant AIM worsened all of those endpoints. The decisive mediator was IL-10, because the benefits of AIM blockade were ablated by recombinant IL-10 [16].

How AIM Is Measured and Observed in Practice

AIM is quantified in serum, plasma, urine, and tissue, and the assay choice determines what you actually learn.

Immunoassays. Enzyme-linked immunosorbent assay (ELISA) is the standard approach for serum AIM. It was used to show that serum AIM concentrations in rheumatoid arthritis patients were dramatically higher than in osteoarthritis patients or healthy controls, and that levels correlated with erythrocyte sedimentation rate, C-reactive protein, and DAS28 disease activity scores [17]. The critical methodological point is whether the assay detects total AIM or only the IgM-free fraction. These are different analytes with different biology, and mixing them up produces contradictory results.

Targeted proteomics. Liquid chromatography-mass spectrometry based targeted proteomics has been used to quantify AIM in serum and urine, including in dogs with acute kidney injury [15]. This approach avoids antibody specificity problems and can resolve species variants.

Western blot and immunohistochemistry. Western blot detects AIM in serum and tissue, and immunohistochemistry localizes it within cells. In canine histiocytic sarcoma, AIM was detected in the cytoplasm of tumor cells, and CD36 was found on the cell membrane, which is consistent with an autocrine loop [18].

Ratio-based interpretation. Because AIM circulates bound to IgM, the AIM/IgM ratio is often more informative than total AIM. Blood AIM/IgM ratios differ among nonsmokers, healthy smokers, and patients with COPD, and the ratio has been examined against exacerbation and mortality outcomes [5]. In IgA nephropathy, serum IgM-free AIM reflected disease activity and glomerular AIM deposition colocalized with mesangial IgA [12].

Comparative and Clinical Relevance

AIM is not a human-only protein. Orthologs exist across mammals, and the species differences are instructive rather than trivial.

Feline AIM is the clearest example. Cats produce both a three-domain and a four-domain variant, and feline AIM binds IgM about 1000-fold more tightly than murine AIM because of a positively charged cluster in the third SRCR domain [4]. Tighter IgM binding means less free AIM at baseline, which would be expected to shift the functional balance toward the bound, inactive pool. This is a hypothesis-generating observation for feline injection-site sarcoma, a tumor that arises in chronic inflammation and contains abundant tumor-associated macrophages [4].

Canine AIM is characteristically expressed in macrophages. Dogs with histiocytic sarcoma had significantly higher serum AIM than healthy dogs, and overexpressing AIM in a histiocytic sarcoma cell line increased growth speed, invasion, apoptosis inhibition, and phagocytic activity [18]. In dogs with acute kidney injury, AIM was detected predominantly in urine and not in the urine of healthy dogs [15].

Human CD5L behaves in ways that connect it to lipid and inflammatory disease. Serum AIM is elevated in sepsis and predicts mortality better than several conventional markers in the studied cohorts [19]. It is elevated in rheumatoid arthritis and tracks disease activity [17]. It deposits in glomeruli in IgA nephropathy [12]. It is secreted by epicardial fat and regulated by catecholamines [6]. And it predicts incident dyslipidemia in women [14]. The through-line is that AIM rises when macrophages are activated and lipid handling is stressed.

The therapeutic angle is active but preclinical. Recombinant AIM has been tested to promote kidney repair [8][10]. Anti-AIM antibodies have been tested to reduce aneurysm progression [13] and to improve sepsis survival [16]. Recombinant AIM eyedrops rescued intraocular pressure recovery in knockout mice [7]. The direction of the intervention flips depending on the disease, which is the central practical challenge of targeting AIM.

Common Mistakes and Limitations

Confusing total AIM with free AIM. These are different analytes. Total AIM includes the IgM-bound pool, which is largely inactive. Free AIM is the functional fraction. Studies that measure only total AIM can miss the biology entirely, and the high-salt acute kidney injury work is the clearest demonstration that dissociation, not absolute concentration, can be the decisive variable [8].

Assuming AIM is always protective. The name is misleading. AIM inhibits apoptosis in macrophages, but that survival signal can be harmful when the macrophages in question are driving chronic inflammation. Blocking AIM improved outcomes in sepsis and aortic aneurysm, while adding AIM worsened them [16][13]. The protein is pleiotropic, and its role depends on the disease [2].

Treating mouse and human data as interchangeable. Species differences in domain number and IgM affinity are large. Feline AIM binds IgM roughly 1000-fold more tightly than murine AIM [4]. Extrapolating mouse thresholds or ratios directly to other species is not safe.

Ignoring the receptor context. AIM requires partners. The kidney repair function depends on KIM-1, and CD36 is the main receptor in several other tissues [8][7]. AIM activity in a given tissue depends on whether the relevant receptor is present.

Overreading biomarker associations. Elevated AIM in sepsis, rheumatoid arthritis, or IgA nephropathy is an association with disease activity or outcome in the studied cohorts. It does not establish that AIM causes the disease, and it does not define a diagnostic threshold that applies outside those cohorts.

Forgetting that AIM is secreted. Because AIM acts at a distance from the cell that makes it, local measurements in tissue and systemic measurements in blood can tell different stories. Epicardial fat CD5L levels differed between patient groups while plasma levels did not [6], which is a direct illustration of compartment-specific biology.

Quick Review

1. AIM (CD5L, Api6, Spalpha) is a secreted SRCR superfamily protein made mainly by macrophages.
2. It circulates bound to IgM pentamers and becomes active only when it dissociates as free AIM.
3. Its founding function is inhibiting macrophage apoptosis, and it also suppresses inflammasome activation via IL-10/STAT3 signaling.
4. It acts as an opsonin for dead cells and debris, working with receptors such as CD36 and KIM-1.
5. It regulates lipid metabolism and drives foamy macrophage formation.
6. The AIM knockout mouse shows impaired macrophage survival plus altered atherosclerosis, obesity, kidney injury, and infection phenotypes.
7. Human CD5L and mouse Aim are orthologs, not identical proteins, and feline AIM binds IgM far more tightly.

Frequently Asked Questions

What does apoptosis inhibitor of macrophage do?

AIM keeps macrophages alive, helps them clear dead cells and debris, and regulates lipid handling. It circulates bound to IgM and acts mainly after dissociating into its free form.

Is AIM the same as CD5L?

Yes. AIM is the protein product of the CD5L gene, and the names AIM, CD5L, Api6, and Spalpha all refer to the same molecule.

Why is AIM called an apoptosis inhibitor?

The name comes from the original finding that AIM suppresses programmed cell death in macrophages. Later work showed it also suppresses inflammasome activation and supports an M2-like macrophage state.

What happens in the AIM knockout mouse?

AIM-deficient mice show impaired macrophage survival and altered phenotypes in atherosclerosis, myocardial infarction, obesity-related lipid handling, kidney injury repair, and several infection models. The direction of the effect depends on the disease.

Does AIM help or harm in disease?

Both, depending on context. Recombinant AIM improves kidney injury repair, while blocking AIM improves survival in sepsis and reduces aortic aneurysm progression.

How is AIM measured in the lab?

Serum and urine AIM are measured by ELISA, targeted mass spectrometry, or western blot. Immunohistochemistry localizes it in tissue, and the AIM/IgM ratio is often more informative than total AIM.

Related Articles

• Wnt Signaling from Macrophages: Mechanisms and Roles
• Feasibility in Specific Aims
• Feline Macrophage Activation Syndrome: Diagnosis and Management
• Apoptosis A Level: Cell Death Explained Simply
• Apoptosis Pathway: Key Steps and Mechanisms
• Stimulate Apoptosis: Mechanisms and Methods for Research

Sources

1. Deletion of Apoptosis Inhibitor of Macrophage (AIM)/CD5L Attenuates the Inflammatory Response and Infarct Size in Acute Myocardial Infarction.
2. The comprehensive role of apoptosis inhibitor of macrophage (AIM) in pathological conditions.
3. Apoptosis inhibitor of macrophage suppress immune responses via IL-10 production and delay bacterial clearance in Mycobacterium avium infection.
4. Apoptosis inhibitor of macrophage (AIM/CD5L) as a potential immunomodulator in feline injection-site sarcoma: a hypothesis on tumor-macrophage interactions.
5. Apoptosis inhibitor of macrophage (AIM)/CD5L is involved in the pathogenesis of COPD.
6. CD5L, Macrophage Apoptosis Inhibitor, Was Identified in Epicardial Fat-Secretome and Regulated by Isoproterenol From Patients With Heart Failure.
7. Apoptosis inhibitor of macrophages/CD5L enhances phagocytosis in the trabecular meshwork cells and regulates ocular hypertension.
8. High salt exacerbates acute kidney injury by disturbing the activation of CD5L/apoptosis inhibitor of macrophage (AIM) protein.
9. Apoptosis inhibitor of macrophage (AIM) contributes to IL-10-induced anti-inflammatory response through inhibition of inflammasome activation.
10. Recombinant apoptosis inhibitor of macrophage protein reduces delayed graft function in a murine model of kidney transplantation.
11. Apoptosis Inhibitor of Macrophages Contributes to the Chronicity of Mycobacterium avium Infection by Promoting Foamy Macrophage Formation.
12. Apoptosis Inhibitor of Macrophage and Acute Inflammation in IgA Nephropathy.
13. Administration of an antibody against apoptosis inhibitor of macrophage prevents aortic aneurysm progression in mice.
14. Serum total apoptosis inhibitor of macrophage, metabolomic signatures, and incident dyslipidemia: A population-based prospective study.
15. Apoptosis Inhibitor of Macrophage (CD5-Like Antigen) in Healthy Dogs and Dogs With Acute Kidney Injury.
16. Therapeutic Targeting of Apoptosis Inhibitor of Macrophage/CD5L in Sepsis.
17. Apoptosis inhibitor of macrophage/CD5L is associated with disease activity in rheumatoid arthritis.
18. Serum level of apoptosis inhibitor of macrophage in dogs with histiocytic sarcoma and its association with the disease.
19. Assessment of Apoptosis Inhibitor of Macrophage/CD5L as a Biomarker to Predict Mortality in the Critically Ill With Sepsis.